The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
The capital expansion program commenced in June 2022 and is expected to complete in 2024
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Investment in response to increased demand for North American-based chemistry services
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Subscribe To Our Newsletter & Stay Updated
